Want to see JP:2183 full AI Analyst Report?
2183 Stock Chart & Stats
¥293.00
-¥1.00(-0.28%)
At close: 4:00 PM EST
¥293.00
-¥1.00(-0.28%)
Day’s Range― - ―
52-Week Range¥198.00 - ¥355.00
Previous CloseN/A
Volume36.50K
Average Volume (3M)14.99K
Market Cap
¥4.65B
Enterprise Value¥1.92K
Total Cash (Recent Filing)¥4.68B
Total Debt (Recent Filing)¥2.04B
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.86%
Share Statistics
EPS (TTM)-167.75
Shares Outstanding24,740,000
10 Day Avg. Volume18,600
30 Day Avg. Volume14,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.46
Price to Sales (P/S)0.67
P/FCF Ratio-3.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.7
Revenue Forecast (FY)¥13.00B
Bulls Say, Bears Say
Bulls Say
CRO Business ModelThe fee-based CRO model serves sponsors that outsource complex clinical development work, creating a recurring need for trial planning, execution, and project support as drug development pipelines advance.
Manageable LeverageModerate leverage provides more financial flexibility than a heavily debt-funded structure and may help Linical absorb operational volatility while it works to restore profitability and cash generation.
Meaningful Equity BaseA still-meaningful equity base offers some balance-sheet support against current losses and reduces immediate reliance on external financing, although continued losses could weaken this cushion over time.
Bears Say
Revenue ContractionThe revenue decline signals weaker project activity or execution and reduces operating leverage in a service business, making recovery dependent on rebuilding sponsor demand and stabilizing the clinical program pipeline.
Sharp Profitability DeteriorationWeak margins and the swing to a large loss indicate that the current cost base is not absorbing lower revenue effectively, raising execution risk and making sustained earnings recovery less certain.
Negative Cash GenerationNegative operating and free cash flow reduces internally generated funding for operations and increases dependence on balance-sheet resources, especially if the earnings downturn and project weakness persist.
Linical Co., Ltd. News
2183 FAQ
What was Linical Co., Ltd.’s price range in the past 12 months?
Linical Co., Ltd. lowest stock price was ¥198.00 and its highest was ¥355.00 in the past 12 months.
What is Linical Co., Ltd.’s market cap?
Linical Co., Ltd.’s market cap is ¥4.65B.
When is Linical Co., Ltd.’s upcoming earnings report date?
Linical Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 83 days.
How were Linical Co., Ltd.’s earnings last quarter?
Linical Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -¥28.16 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Linical Co., Ltd. overvalued?
According to Wall Street analysts Linical Co., Ltd.’s price is currently Overvalued.
Does Linical Co., Ltd. pay dividends?
Linical Co., Ltd. pays a Annually dividend of ¥8 which represents an annual dividend yield of 3.86%. See more information on Linical Co., Ltd. dividends here
What is Linical Co., Ltd.’s EPS estimate?
Linical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Linical Co., Ltd. have?
Linical Co., Ltd. has 24,740,000 shares outstanding.
What happened to Linical Co., Ltd.’s price movement after its last earnings report?
Linical Co., Ltd. reported an EPS of -¥28.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.914%.
Which hedge fund is a major shareholder of Linical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2183
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Linical Co., Ltd.
Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariats; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.